Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.
about
Pharmacokinetic drug interactions in liver disease: An updateInteraction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sourcesApplication of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin.The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adultsThe influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney.Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsRole of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism.Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.Pharmacogenomics: challenges and opportunitiesCytochrome P450 reaction-phenotyping: an industrial perspective.Role of OATP transporters in the disposition of drugs.Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Transporter pharmacogenetics and statin toxicity.Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testingLack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients.Race differences: modeling the pharmacodynamics of rosuvastatin in Western and Asian hypercholesterolemia patients.Exploring differences in drug doses between Japan and Western countries.The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update.Obesity-related non-communicable diseases: South Asians vs White Caucasians.Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.Optimizing the in vitro and clinical assessment of drug interaction risk by understanding co-medications in patient populations.Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions.Global analysis of genetic variation in SLCO1B1.Effects of the Chinese herbal formula "Zuojin Pill" on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype.Toward Prospective Prediction of Pharmacokinetics in OATP1B1 Genetic Variant Populations.ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients.Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function.Effects of Seijo-bofu-to, a traditional Japanese herbal medicine containing furanocoumarin derivatives, on the drug-metabolizing enzyme activities in healthy male volunteers.Pharmacogenomic diversity in Singaporean populations and Europeans.Medicine, genetics and race: the case of cardiovascular diseases
P2860
Q26774479-5C1B9DD6-D5EF-43E1-94D0-EF618D4406B2Q28250490-07EF381A-AE50-499A-AE38-E7B42EE464AFQ33994570-68DB1DEB-EF27-41DA-9872-B0C02C332013Q34276618-A60BDA9A-32AB-448C-8D92-8F11C1D8E260Q34510611-A9F9D22C-68C3-4B3C-9FF8-7812C6DB4772Q34613443-6ACBBC88-51D6-40EA-BED2-67DE745D98A4Q34777362-FD5E1BEB-49E3-40B9-B4F5-976589D9F414Q35915932-0A8E89E0-F887-4634-845B-F8FF10446CC2Q36362377-7A55587F-7507-4F22-8CD8-CB6CE9B6503FQ36562502-843645FC-DA4A-42DA-994B-D83ED7E63421Q36658763-43158127-5F7B-4548-9915-82E037A1506BQ36960539-61A92AB0-0EAB-43F5-BED2-3665BAC78B50Q37074085-31E2E606-311B-409C-BC69-277620714297Q37086418-72537F8A-E871-4E70-8B61-01293E6A9713Q37627544-93178D22-BC9A-4569-8F7B-014E5C43A56CQ37652863-4FBCB1EB-8BFD-4A91-A495-AE62A4B48CFDQ37728163-88B35A71-8B82-4AF4-85EA-3A33DFA4464BQ37729822-694D609F-3A31-4DB9-9D3E-8A5E537A6571Q37735690-C9029A33-5D91-457C-B0C4-1329B3B99F09Q37770251-83323015-9B22-46DE-9DC4-4EE884942713Q37774235-101DC7E4-70B4-4A59-A24E-D29CD5091100Q38084901-37BA8FB3-3FF7-4775-AF8C-EE6CAC5B7865Q38099049-41AFB056-EE3F-430C-A30B-9DE2AE8EF1BBQ38160088-EBA8DE64-C3CD-40EA-8637-34440702C020Q39340828-61899586-4916-450B-8AAD-E33913A7F60EQ39882089-71A611F6-D3CE-4891-8C4C-82D3F2F046AEQ41706349-AC1F355F-9B6F-4778-AD22-7373293B4C96Q43174441-3234E3DB-94F0-4F24-A470-7621ACE2D102Q45993642-F14789A7-3118-4493-88B9-5BEC7EA3C6FDQ46062183-4A7FACCE-66C5-4ECD-B92B-63F36F18A9C2Q46237124-72A6E36E-0D1E-46EB-9AA7-FFE5ECFC849BQ47664139-A0671E67-4C58-418D-B6A4-62ECACEEBA93Q53541756-7E29AD8D-3C2E-4C98-B0B2-64D1EA700FD4Q57337013-4472F004-1A32-4F4C-9FDD-F96F57EE08D4
P2860
Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Evaluation of inhibitory drug ...... ymorphisms must be considered.
@ast
Evaluation of inhibitory drug ...... ymorphisms must be considered.
@en
type
label
Evaluation of inhibitory drug ...... ymorphisms must be considered.
@ast
Evaluation of inhibitory drug ...... ymorphisms must be considered.
@en
prefLabel
Evaluation of inhibitory drug ...... ymorphisms must be considered.
@ast
Evaluation of inhibitory drug ...... ymorphisms must be considered.
@en
P2093
P1476
Evaluation of inhibitory drug ...... ymorphisms must be considered.
@en
P2093
Anne N Nafziger
Joseph S Bertino
Lois S Lee
P356
10.1016/J.CLPT.2005.04.006
P407
P577
2005-07-01T00:00:00Z